1,915 results on '"Kröger, N."'
Search Results
152. Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma
153. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)
154. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation
155. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome
156. Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up
157. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus
158. Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT)
159. Aldehyde dehydrogenase activity as a marker for the quality of hematopoietic stem cell transplants
160. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants
161. Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age>55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning
162. Stem cell transplantation from identical twins in patients with myelodysplastic syndromes
163. P3.9 - Flexibler, amperometrischer Biosensor basierend auf der Seide des Seidenspinners Bombyx mori
164. Isolated HLA-C mismatches in unrelated donor transplantation for CML
165. DEGRO 2004: 10. Jahreskongress der Deutschen Gesellschaft für Radioonkologie
166. Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma
167. Reduced-intensity conditioning with busulfan and fludarabine with or without antithymocyte globulin in HLA-identical sibling transplantation – a retrospective analysis
168. Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML
169. Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients
170. A new conditioning regimen involving total marrow irradiation, busulfan and cyclophosphamide followed by autologous PBSCT in patients with advanced multiple myeloma
171. ATG as part of the conditioning regimen reduces transplant-related mortality (TRM) and improves overall survival after unrelated stem cell transplantation in patients with chronic myelogenous leukemia (CML)
172. Non-overt disseminated intravascular coagulation in patients during treatment with antithymocyte globulin for unrelated allogeneic hematopoietic stem cell transplantation
173. Solid-state 29Si MAS NMR studies of diatoms: structural characterization of biosilica deposits
174. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias
175. Impact of physiological BM CD10 + CD19 + B-cell precursors (haematogones) in the post-transplant period in patients with AML
176. Hematopoietic SCT in Europe: data and trends in 2011
177. Hematopoietic Stem and Progenitor Cell Mobilization in Mice and Humans by a First-in-Class Mirror-Image Oligonucleotide Inhibitor of CXCL12
178. Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with < 10% BM blasts: a report from EBMT
179. Prophylaxis and treatment of graft-versus-host disease: EBMT - ELN working group recommendations for a standardized practice: 296
180. Second allogeneic haematopoietic stem cell transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors: 196
181. Reduced versus standard conditioning in MDS/sAML: preliminary results of a prospective, randomized Phase III trial of Chronic Malignancies Working Party of the EBMT (RICMAC-Trial): 201
182. Tandem autologous/reduced-intensity allogeneic stem cell transplantation versus autologous transplantation in multiple myeloma - update of the EBMT-NMAM2000 study at 96 months median follow-up: 197
183. Use of second generation tyrosine kinase inhibitors prior to allogeneic stem cell transplantation in chronic myeloid leukaemia: 198
184. Impact of graft-versus-host disease on relapse after allogeneic stem cell transplantation: an EBMT megafile study: 200
185. Allogeneic HSCT in patients with 17p- CLL: first results of a non-interventional prospective study: 199
186. Higher probability of survival in complete remission following tandem autologous/reduced-intensity allogeneic transplantation compared to autologous transplantation alone in the NMAM2000 multiple myeloma trial as estimated by multistate models: O158
187. Prospective analysis of prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by allogeneic haematopoietic stem cell transplantation: a study on behalf of the MDS subcommittee of the Chronic Malignancies Working Party of the EBM: O157
188. The effect of non-myeloablative conditioning (NMA) versus reduced-intensity conditioning (RIC) in chronic lymphocytic leukaemia (CLL) undergoing allogeneic haematopoietic cell transplantation (allo-HCT): a retrospective EBMT analysis: O153
189. Evaluation of BM cytomorphology after allo-SCT in patients with MDS
190. Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin
191. TNFα, interleukin-10 and interleukin-18 expression in cells of the bronchoalveolar lavage in patients with pulmonary complications following bone marrow or peripheral stem cell transplantation: a preliminary study
192. Stem cell mobilisation with 16 μg/kg vs 10 μg/kg of G-CSF for allogeneic transplantation in healthy donors
193. In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors
194. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma
195. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome
196. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma
197. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients
198. Circulating CD34+ cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT
199. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually
200. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.